Safety, antigenicity, and efficacy of a recombinant coccidioidomycosis vaccine in cynomolgus macaques (Macaca fascicularis)

Suzanne M. Johnson, Nicholas W. Lerche, Demosthenes Pappagianis, Joann L. Yee, John N Galgiani, Richard F. Hector

Research output: Chapter in Book/Report/Conference proceedingConference contribution

19 Citations (Scopus)

Abstract

The safety, immunogenicity and efficacy of recombinant Ag2/PRA106 + CSA chimeric fusion protein (CFP) vaccine in ISS/Montanide adjuvant-administered intramuscular (IM) was assessed in adult female cynomolgus macaques challenged with Coccidioides posadasii. Animals received three immunizations with either 5 μg CFP, 50-μg CFP, or adjuvant alone and were challenged 4 weeks following the final immunization. Although significant antibody response was produced in response to vaccination, there were no discernable adverse effects, suggesting that the vaccine was well tolerated. Upon intratracheal challenge, all animals showed evidence of disease. Two animals that received 5-μg doses of CFP were euthanatized prior to the study's end because of severe symptoms. Animals vaccinated with 50-μg doses of CFP showed evidence of enhanced sensitization compared to adjuvant controls and animals vaccinated with 5-μg doses of CFP. This was based on higher serum anti-CFP titers, enhanced secretion of interferon-gamma (IFN-γ) from stimulated bronchoalveolar lavage mononuclear cells (BALMC), reduced pulmonary radiologic findings following intratracheal challenge, reduced terminal complement fixation titers, and reduced necropsy findings. Overall the vaccine was well tolerated, induced sensitization, and resulted in a protective response when given at the higher 50-μg dose. Additional experiments may be needed to optimize the vaccination and to confer greater protection against lethal challenge.

Original languageEnglish (US)
Title of host publicationAnnals of the New York Academy of Sciences
Pages290-300
Number of pages11
Volume1111
DOIs
StatePublished - Sep 2007

Publication series

NameAnnals of the New York Academy of Sciences
Volume1111
ISSN (Print)00778923
ISSN (Electronic)17496632

Fingerprint

Coccidioidomycosis
Synthetic Vaccines
Macaca fascicularis
Macaca
Fusion reactions
Safety
Animals
Proteins
Immunization
Vaccines
Vaccination
Coccidioides
Bronchoalveolar Lavage
Interferon-gamma
Antibody Formation
Lung
Antibodies
Serum

Keywords

  • Coccidioides
  • Coccidioidomycosis
  • Experimental model
  • Immunity
  • Infection
  • Primate
  • Vaccine

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Johnson, S. M., Lerche, N. W., Pappagianis, D., Yee, J. L., Galgiani, J. N., & Hector, R. F. (2007). Safety, antigenicity, and efficacy of a recombinant coccidioidomycosis vaccine in cynomolgus macaques (Macaca fascicularis). In Annals of the New York Academy of Sciences (Vol. 1111, pp. 290-300). (Annals of the New York Academy of Sciences; Vol. 1111). https://doi.org/10.1196/annals.1406.042

Safety, antigenicity, and efficacy of a recombinant coccidioidomycosis vaccine in cynomolgus macaques (Macaca fascicularis). / Johnson, Suzanne M.; Lerche, Nicholas W.; Pappagianis, Demosthenes; Yee, Joann L.; Galgiani, John N; Hector, Richard F.

Annals of the New York Academy of Sciences. Vol. 1111 2007. p. 290-300 (Annals of the New York Academy of Sciences; Vol. 1111).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Johnson, SM, Lerche, NW, Pappagianis, D, Yee, JL, Galgiani, JN & Hector, RF 2007, Safety, antigenicity, and efficacy of a recombinant coccidioidomycosis vaccine in cynomolgus macaques (Macaca fascicularis). in Annals of the New York Academy of Sciences. vol. 1111, Annals of the New York Academy of Sciences, vol. 1111, pp. 290-300. https://doi.org/10.1196/annals.1406.042
Johnson SM, Lerche NW, Pappagianis D, Yee JL, Galgiani JN, Hector RF. Safety, antigenicity, and efficacy of a recombinant coccidioidomycosis vaccine in cynomolgus macaques (Macaca fascicularis). In Annals of the New York Academy of Sciences. Vol. 1111. 2007. p. 290-300. (Annals of the New York Academy of Sciences). https://doi.org/10.1196/annals.1406.042
Johnson, Suzanne M. ; Lerche, Nicholas W. ; Pappagianis, Demosthenes ; Yee, Joann L. ; Galgiani, John N ; Hector, Richard F. / Safety, antigenicity, and efficacy of a recombinant coccidioidomycosis vaccine in cynomolgus macaques (Macaca fascicularis). Annals of the New York Academy of Sciences. Vol. 1111 2007. pp. 290-300 (Annals of the New York Academy of Sciences).
@inproceedings{a2795c57e2b0495d8a918bff4ddd5e7d,
title = "Safety, antigenicity, and efficacy of a recombinant coccidioidomycosis vaccine in cynomolgus macaques (Macaca fascicularis)",
abstract = "The safety, immunogenicity and efficacy of recombinant Ag2/PRA106 + CSA chimeric fusion protein (CFP) vaccine in ISS/Montanide adjuvant-administered intramuscular (IM) was assessed in adult female cynomolgus macaques challenged with Coccidioides posadasii. Animals received three immunizations with either 5 μg CFP, 50-μg CFP, or adjuvant alone and were challenged 4 weeks following the final immunization. Although significant antibody response was produced in response to vaccination, there were no discernable adverse effects, suggesting that the vaccine was well tolerated. Upon intratracheal challenge, all animals showed evidence of disease. Two animals that received 5-μg doses of CFP were euthanatized prior to the study's end because of severe symptoms. Animals vaccinated with 50-μg doses of CFP showed evidence of enhanced sensitization compared to adjuvant controls and animals vaccinated with 5-μg doses of CFP. This was based on higher serum anti-CFP titers, enhanced secretion of interferon-gamma (IFN-γ) from stimulated bronchoalveolar lavage mononuclear cells (BALMC), reduced pulmonary radiologic findings following intratracheal challenge, reduced terminal complement fixation titers, and reduced necropsy findings. Overall the vaccine was well tolerated, induced sensitization, and resulted in a protective response when given at the higher 50-μg dose. Additional experiments may be needed to optimize the vaccination and to confer greater protection against lethal challenge.",
keywords = "Coccidioides, Coccidioidomycosis, Experimental model, Immunity, Infection, Primate, Vaccine",
author = "Johnson, {Suzanne M.} and Lerche, {Nicholas W.} and Demosthenes Pappagianis and Yee, {Joann L.} and Galgiani, {John N} and Hector, {Richard F.}",
year = "2007",
month = "9",
doi = "10.1196/annals.1406.042",
language = "English (US)",
isbn = "1573316881",
volume = "1111",
series = "Annals of the New York Academy of Sciences",
pages = "290--300",
booktitle = "Annals of the New York Academy of Sciences",

}

TY - GEN

T1 - Safety, antigenicity, and efficacy of a recombinant coccidioidomycosis vaccine in cynomolgus macaques (Macaca fascicularis)

AU - Johnson, Suzanne M.

AU - Lerche, Nicholas W.

AU - Pappagianis, Demosthenes

AU - Yee, Joann L.

AU - Galgiani, John N

AU - Hector, Richard F.

PY - 2007/9

Y1 - 2007/9

N2 - The safety, immunogenicity and efficacy of recombinant Ag2/PRA106 + CSA chimeric fusion protein (CFP) vaccine in ISS/Montanide adjuvant-administered intramuscular (IM) was assessed in adult female cynomolgus macaques challenged with Coccidioides posadasii. Animals received three immunizations with either 5 μg CFP, 50-μg CFP, or adjuvant alone and were challenged 4 weeks following the final immunization. Although significant antibody response was produced in response to vaccination, there were no discernable adverse effects, suggesting that the vaccine was well tolerated. Upon intratracheal challenge, all animals showed evidence of disease. Two animals that received 5-μg doses of CFP were euthanatized prior to the study's end because of severe symptoms. Animals vaccinated with 50-μg doses of CFP showed evidence of enhanced sensitization compared to adjuvant controls and animals vaccinated with 5-μg doses of CFP. This was based on higher serum anti-CFP titers, enhanced secretion of interferon-gamma (IFN-γ) from stimulated bronchoalveolar lavage mononuclear cells (BALMC), reduced pulmonary radiologic findings following intratracheal challenge, reduced terminal complement fixation titers, and reduced necropsy findings. Overall the vaccine was well tolerated, induced sensitization, and resulted in a protective response when given at the higher 50-μg dose. Additional experiments may be needed to optimize the vaccination and to confer greater protection against lethal challenge.

AB - The safety, immunogenicity and efficacy of recombinant Ag2/PRA106 + CSA chimeric fusion protein (CFP) vaccine in ISS/Montanide adjuvant-administered intramuscular (IM) was assessed in adult female cynomolgus macaques challenged with Coccidioides posadasii. Animals received three immunizations with either 5 μg CFP, 50-μg CFP, or adjuvant alone and were challenged 4 weeks following the final immunization. Although significant antibody response was produced in response to vaccination, there were no discernable adverse effects, suggesting that the vaccine was well tolerated. Upon intratracheal challenge, all animals showed evidence of disease. Two animals that received 5-μg doses of CFP were euthanatized prior to the study's end because of severe symptoms. Animals vaccinated with 50-μg doses of CFP showed evidence of enhanced sensitization compared to adjuvant controls and animals vaccinated with 5-μg doses of CFP. This was based on higher serum anti-CFP titers, enhanced secretion of interferon-gamma (IFN-γ) from stimulated bronchoalveolar lavage mononuclear cells (BALMC), reduced pulmonary radiologic findings following intratracheal challenge, reduced terminal complement fixation titers, and reduced necropsy findings. Overall the vaccine was well tolerated, induced sensitization, and resulted in a protective response when given at the higher 50-μg dose. Additional experiments may be needed to optimize the vaccination and to confer greater protection against lethal challenge.

KW - Coccidioides

KW - Coccidioidomycosis

KW - Experimental model

KW - Immunity

KW - Infection

KW - Primate

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=35348850079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348850079&partnerID=8YFLogxK

U2 - 10.1196/annals.1406.042

DO - 10.1196/annals.1406.042

M3 - Conference contribution

C2 - 17347333

AN - SCOPUS:35348850079

SN - 1573316881

SN - 9781573316880

VL - 1111

T3 - Annals of the New York Academy of Sciences

SP - 290

EP - 300

BT - Annals of the New York Academy of Sciences

ER -